Farnesyltransferase inihibitors in hematologic malignancies
- 1 July 2007
- journal article
- review article
- Published by Elsevier in Blood Reviews
- Vol. 21 (4) , 173-182
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKTBlood, 2005
- Dose-Ranging Pharmacodynamic Study of Tipifarnib (R115777) in Patients With Relapsed and Refractory Hematologic MalignanciesJournal of Clinical Oncology, 2004
- The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitroEuropean Journal of Haematology, 2004
- Phase II Study of R115777, a Farnesyl Transferase Inhibitor, in Myelodysplastic SyndromeJournal of Clinical Oncology, 2004
- Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 settingBlood, 2003
- Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitroBlood, 2003
- In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasiaLeukemia, 2003
- The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cellsLeukemia, 2003
- Myelofibrosis with Myeloid MetaplasiaNew England Journal of Medicine, 2000
- Proteins regulating Ras and its relativesNature, 1993